


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A compound of formula (I):



wherein:

A is CH₂CH₂ or A is absent;

R¹ is C₃₋₇ cycloalkyl (substituted by one or two fluorine atoms and optionally further substituted by C₁₋₄ alkyl) or N-linked heterocyclyl (substituted by one or two fluorine atoms and optionally further substituted by C₁₋₄ alkyl);

R² is C₃₋₆ alkyl or C₃₋₆ cycloalkyl, or phenyl or heteroaryl either of which is optionally substituted by halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, S(O)_n(C₁₋₄ alkyl), nitro, cyano or CF₃;

R^{2a}, R⁴ and R^{4a} are, independently, hydrogen or C₁₋₄ alkyl;

R³ and R^{3a} are, independently, hydrogen or C₁₋₄ alkyl or C₁₋₄ alkoxy;

R⁵ is hydrogen, C₁₋₄ alkyl (optionally substituted by halogen, hydroxy, C₁₋₄ alkoxy, C₃₋₇ cycloalkyl, SH, C₁₋₄ alkylthio, cyano or S(O)_q(C₁₋₄ alkyl)), C₃₋₄ alkenyl, C₃₋₄ alkynyl or C₃₋₇ cycloalkyl;


R⁶ is phenyl, heteroaryl, phenylNH, heteroarylNH, phenyl(C₁₋₂)alkyl, heteroaryl(C₁₋₂)alkyl, phenyl(C₁₋₂ alkyl)NH or heteroaryl(C₁₋₂ alkyl)NH;

wherein the phenyl and heteroaryl rings of any of the foregoing are, unless stated otherwise, independently optionally substituted by halo, cyano, nitro, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, S(O)_mC₁₋₄ alkyl, S(O)₂NR⁷R⁸, NHS(O)₂(C₁₋₄ alkyl), NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂, NHC(O)NH₂, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), CO₂H, CO₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃, CHF₂, CH₂F, CH₂CF₃ or OCF₃; R⁷ and R⁸ are, independently, hydrogen or C₁₋₄ alkyl, or together with a nitrogen or oxygen atom, may join to form a 5- or 6-membered ring which is optionally substituted with C₁₋₄ alkyl, C(O)H or C(O)(C₁₋₄ alkyl); m, n and q are, independently, 0, 1 or 2; or a pharmaceutically acceptable salt thereof or a solvate thereof.

2. (Original) A compound as claimed in claim 1 wherein R^{2a}, R³, R^{3a} and R⁴ are all hydrogen.
3. (Currently amended) A compound as claimed in claim 1-~~or 2~~ wherein R^{4a} is hydrogen or methyl.
4. (Currently amended) A compound as claimed in claim 1,~~2 or 3~~ wherein R¹ is C₃₋₇ cycloalkyl (substituted by 1 or 2 fluorine atoms and optionally further substituted by C₁₋₄ alkyl).
5. (Currently amended) A compound as claimed in claim 1,~~2, 3 or 4~~ wherein R¹ is 4,4-di-fluoro-cyclohexyl, 3,3-di-fluoro-cyclopentyl or 3,3-di-fluoro-cyclobutyl.
6. (Currently amended) A compound as claimed in claim 1,~~2, 3, 4 or 5~~ wherein R² is phenyl or 6-membered heteroaryl optionally substituted by halogen or CF₃.
7. (Currently amended) A compound as claimed in claim 1,~~2, 3, 4, 5 or 6~~ wherein R⁵ is ethyl.

8. (Currently amended) A compound as claimed in claim 1, ~~2, 3, 4, 5, 6 or 7~~ wherein R⁶ is phenyl, heteroaryl, phenylNH, heteroarylNH, phenyl(C₁₋₂)alkyl, heteroaryl(C₁₋₂)alkyl, phenyl(C₁₋₂ alkyl)NH or heteroaryl(C₁₋₂ alkyl)NH (for example phenyl or phenylCH₂); wherein the phenyl and heteroaryl rings of R⁶ are substituted by S(O)₂C₁₋₄ alkyl, and optionally further substituted by one or more of halo, cyano, nitro, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, S(O)_mC₁₋₄ alkyl, S(O)₂NR⁷R⁸, NHS(O)₂(C₁₋₄ alkyl), NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂, NHC(O)NH₂, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), CO₂H, CO₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃, CHF₂, CH₂F, CH₂CF₃ or OCF₃; wherein m, R⁷ and R⁸ are as defined in claim 1.

9. (Original) A process for the preparation of a compound of formula (I) as claimed in claim 1, wherein A is absent, comprising treating a compound of formula (II):



with:

an acid chloride of formula R¹C(O)Cl, in the presence of a base and in a suitable solvent; or,

an acid of formula R¹CO₂H, in the presence of a suitable coupling agent, a suitable base and in a suitable solvent.

10. (Original) A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1, and a pharmaceutically acceptable adjuvant, diluent or carrier.

11-12. (Cancelled)

13. (Currently amended) A method, comprising:

of treating a chemokine mediated disease state in a warm blooded animal suffering from, or at risk of, said disease, which comprises administering to an animal in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1.